Chromogranin B (CHGB) is the major matrix protein in human catecholamine storage vesicles. CHGB genetic variation alters catecholamine secretion and blood pressure. Here, effective Chgb protein under-expression was achieved by siRNA in PC12 cells, resulting in~48% fewer secretory granules on electron microscopy, diminished capacity for catecholamine uptake (by~79%), and a~73% decline in stores available for nicotinic cholinergic-stimulated secretion. In vivo, loss of Chgb in knockout mice resulted in a~35% decline in chromaffin granule abundance and~44% decline in granule diameter, accompanied by unregulated catecholamine release into plasma. Over-expression of CHGB was achieved by transduction of a CHGB-expressing lentivirus, resulting in~127% elevation in CHGB protein, with~122% greater abundance of secretory granules, but only~14% increased uptake of catecholamines, and no effect on nicotinic-triggered secretion. Human CHGB protein and its proteolytic fragments inhibited nicotinic-stimulated catecholamine release by~72%. One conserved-region CHGB peptide inhibited nicotinic-triggered secretion by up to~41%, with partial blockade of cationic signal transduction. We conclude that bi-directional quantitative derangements in CHGB abundance result in profound changes in vesicular storage and release of catecholamines. When processed and released extra-cellularly, CHGB proteolytic fragments exert a feedback effect to inhibit catecholamine secretion, especially during nicotinic cholinergic stimulation. The sympathetic branch of the autonomic system exerts minute-to-minute control over the circulation. Sympathoadrenal catecholamine secretion is exocytotic (all-or-none), releasing not just catecholamines but also the proteins with which catecholamines are co-stored. The chromogranins/ secretogranins comprise a family of acidic, soluble proteins that are widely stored in secretory granules with hormones, transmitters, and neuropeptides throughout the endocrine and nervous systems (Huttner et al. 1991; Taupenot et al. 2003) .
Chromogranin B (CHGB), first described in 1980s, (Falkensammer et al. 1985; Rosa et al. 1985) seems to be the quantitatively most abundant matrix protein in the core of human catecholamine storage vesicles (O 'Connor et al. 1984; Schober et al. 1987) . Expression studies in chromaffin cells suggest that CHGB plays a functional role in secretory vesicle biogenesis (Huh et al. 2003) .
CHGB may have both extra-cellular and intra-cellular roles in the neuroendocrine system. Extracellular roles for CHGB are dependent on its proteolytic processing within secretory granules (Gill et al. 1991) to form smaller peptides; such peptides may have a role in the neuroendocrine/ sympathoadrenal stress response to systemic infection (Taupenot et al. 2003) , and CHGB fragments may also play an autocrine inhibitory role on the release of co-stored hormones, such as insulin (Karlsson et al. 2000) . Within chromaffin cells and sympathetic axons, CHGB functions in sorting and trafficking of peptide hormone and neuropeptide precursors to secretory granules (Natori and Huttner 1996) , perhaps as triggers to secretory granulogenesis (Huh et al. 2003) .
Hypertension is a complex trait in which deranged autonomic control of the circulation may be an early etiological culprit (Binder 2007) . Expression of CHGB may mark the action of quantitative trait locus (including the CHGB locus itself) influencing exocytotic sympathoadrenal activity (Greenwood et al. 2004 (Greenwood et al. , 2006 . CHGB is over-expressed in rodent models of genetic (Schober et al. 1989; O'Connor et al. 1999) as well as acquired (Takiyyuddin et al. 1993) hypertension, thus suggesting augmented sympathoadrenal activity in the pathogenesis of these syndromes. Therefore, CHGB gives rise to early, pathogenic 'intermediate phenotypes' (Lillie and O 'Connor 2006) for exploration of sympathoadrenal activity in human essential hypertension. Indeed, we reported that two common CHGB promoter SNPs, A-296C (rs236140) and A-261T (rs236141), are strongly associated with hypertension in the population (Zhang et al. 2009 (Zhang et al. , 2010 , while in CHGB knockout (CHGB[À/À]) mice, we observed substantial elevations in both systolic blood pressure and diastolic blood pressure (Zhang et al. 2009) . In this report, we have studied how CHGB quantitative variation (both over-and under-expression) affects not only secretory granulogenesis, but also catecholamine uptake, storage, and exocytotic release. We also describe the effects of novel CHGB fragments upon catecholamine release and its nicotinic cholinergic signal transduction pathway.
Methods
Chromaffin cell biology Rat pheochromocytoma (PC12) cells were cultured in a medium containing Dulbecco's modified Eagle's medium 3 with high glucose (cat#: 11965; Invitrogen, Carlsbad, CA, USA) 4 , 10% horse serum, 5% fetal bovine serum, and 19 penicillin/streptomycin/glutamine. The cells were cultured in an incubator with 6% CO 2 at 37°C, and cell passage number (since initiation of the line) was between 10 and 25 in these experiments.
Secretion of catecholamines from chromaffin cells
Norepinephrine secretion from PC12 cells was assayed as described previously (Biswas et al. 2008) . After washing, cells treated with nicotine (60 lM; for nicotinic cholergic stimulation) or KCl (55 mM; for membrane depolarization) in physiological secretion medium. Each experiment was repeated three times.
Transmission electron microscopy
Transmission electron microscopy on cells/tissues was conducted as previously described (Courel et al. 2006) .
Silencing CHGB expression by small interfering RNA (siRNA) in PC12 cells We used a rat CHGB siRNA siGENOME 'smart pool' (Cat# M-099320-00; Dharmacon) 5 . One day before transfection, PC12 cells were grown on poly-L-lysine-coated 12-well plates and transfected for 48 h with 30, 15, or 7.5 nmol/well siRNA using the Transfectin reagent (Bio-Rad Laboratories, Hercules, CA, USA). Silencing of CHGB expression was evaluated by immunoblotting at the protein level and real-time PCR at the mRNA level. A control siRNA (Cat#: D-001210-01-05; Dharmacon) pre-designed to minimize off-target effects was used as a transfection negative control. The effect of reduced expression of CHGB on dense-core secretory granule abundance was examined by transmission electron microscopy (EM). The anti-CHGB antibody (C-19; catalog #: sc-1489; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 6 was a goat polyclonal IgG (provided at 200 lg/mL, and used at 1 : 3000) for detecting CHGB of rat or human origin.
CHGB ablation in vivo: knockout mice, transmission EM, and catecholamine release Mouse studies were conducted with the approval of the UCSD Animal Subjects Committee, and the ARRIVE guidelines were followed. CHGB knockout mice were generated from mouse embryonic stem cells by homologous recombination, as previously described (Zhang et al. 2009; Diaz-Vera et al. 2010) . The effect of CHGB knockout on dense-core secretory granule abundance was examined by transmission EM. Plasma catecholamines were investigated by high-performance liquid chromatography coupled to an electrochemical detection (HPLC-ECD) system.
Over-expression of CHGB in PC12 cells by transduction of a CHGB lentivirus Human cDNA clone hCHGB-pCMV6XL5 (Cat#: SC119004; Origene, Rockville, MD, USA) was used as template. The 5′ primer, 5′-agcCCCGGGatgcagccaacgctgcttct -3′, includes a SmaI site (capitalized), while the 3′ primer, 5′-caaGTCGACtcagcccctttggctgaatt -3′, includes a SalI site (capitalized). The 2034 bp PCR product was digested with SmaI and SalI (New England Biolab) 7 , purified (Cat#: 28074; Qiagen, Valencia, CA, USA) 8 , and ligated into corresponding site of SIN18-human phosphoglycerate kinase (hPGK)-tdTomato-2A peptide, self-cleavage (T2A) vector to generate SIN18-hPGK-tdTomato- T2A-hCHGB 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 lentiviral vector plasmid ( Figure S1 ). The SIN18-hPGK-tdTomato is used as control lentiviral vector.
The standard operation procedure of lentivirus production is as described (Tiscornia et al. 2006) . Briefly, three plasmids (the lentiviral vector plasmid, the packaging plasmid pCMVDR8.74, and the vesicular stomatitis virus glycoprotein expression plasmid pMD.G) are mixed in a ratio of 3 : 2 : 1 for transient transfection into HEK293T cells using the calcium phosphate method. Unconcentrated viral supernatant is collected every 24 h up to 4 days post-transfection, and a commercially available serum-free ultraculture medium (Bio-Whitttaker #12-725F) 9 with 1 mM L-glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin is used to refeed the transfected plate. The pooled viral supernatant is filtered through 0.22 lm pores, followed by concentration and purification by 20% sucrose gradient centrifugation at 21 000 rpm 10 for 2 h. The viral lysate is resuspended in 19 Hank's Balanced Salt Solution, followed by flow cytometry titration in 293T cells.
For lentiviral transduction, concentrated viral supernatant was added into PC12 cells at a multiplicity of infection of 0.5, and incubated at 37°C overnight. Cells were subjected to culture, experiment, or analysis 72 h post-transduction.
Flow cytometry PC12 cells grown on 100-mm plates and infected with the lentihPGK-tdTomato-T2A-hCHGB or lenti-hPGK-tdTomato-T2A control viruses were suspended in Accutase detachment solution (Innovative Cell Technologies) at a concentration of 2 9 10 6 cells/mL. Cells (7 9 10 6 /sample) were analyzed for tdTomato fluorescence using a MoFlo cell sorter (DakoCytomation) 11
. Fluorescence-activated cell sorting achieved the isolation of lentivirusinfected cells. An aliquot of each cell sample was processed for immunocytochemistry (anti-HA monoclonal antibody) to evaluate the expression of CHGB, and the remaining cells were processed for characterization by biochemistries and imaging by transmission electron microscopy.
Prokaryotic expression and purification of CHGB: pET-hCHGB-6-His Human CHGB cDNA encoding the mature protein (minus the 20-residue signal peptide) was excised by PCR from the eukaryotic expression plasmid hCHGB-pCMV6XL5 (Cat#: SC119004, Origene) as template. The 5′ primer, 5′-gtcCATATGatgccagtggataacaggaa-3′ is preceded by a NdeI site (capitalized) and the 3′ primer, 5′-tgaGTCGACgcccctttggctgaatttct-3′, is preceded by a SalI site (capitalized). The PCR product was digested with NdeI and SalI (New England Biolab) and gel-purified (Cat#: 28074; Qiagen). The resulting fragment of 1974 base pairs was directionally cloned into the expression vector, pET-21a-d (Novagen, Madison, WI, USA). The final construct was designated to encode the mature (i.e., minus signal peptide) human CHGB (657 residues) with addition of the residues VDKLAAALEHHHHHH at the carboxy-terminus (thus a total of 682 residues for the final recombinant protein). The nucleotide sequences of the PCR products and the junction regions between the insert and the vector were verified from both strands by direct dideoxy-capillary sequencing.
BL21(DE3)pLysS (Novagen) competent E.coli were transformed with the pET-(hCHGB-6-His) plasmid. Cells were induced with isopropyl b-D-thiogalactopyranoside; 1 mM, and grown in LB broth containing ampicillin (50 lg/mL) at 37°C until an A 600 of 0.8 was reached. The recombinant protein was purified as described previously using its 6-His affinity tag (Taylor et al. 2000) . Protein concentration was determined by Bio-Rad protein assay reagent (Bio-Rad Laboratories). Aliquotted protein was stored at À70°C until further use.
Endoproteolytic cleavage of CHGB Plasmin is serine protease found in chromaffin cells that can process chromogranin A (CHGA) to its bio-active catestatin fragment (Conlon et al. 1992; Parmer et al. 2000; Jiang et al. 2001) . In order to liberate a 'catestatin-like' peptide from CHGB, we thus turned to plasmin as a protease. Purified human recombinant CHGB protein (10 lmol/reaction) was incubated with human plasmin (EC_3.4.21.7, 2 lmol/reaction; Calbiochem catalog #527624; specific activity 10 U/mg protein) in digestion buffer (10 mM TrisHCl, pH 8.0; 0.15 M NaCl) at 37°C for 30 min. The reaction was terminated by the addition of aprotinin (2.5 lM). For secretion assay, the cells were treated with nicotine (60 lM) in secretion medium, either alone or in combination with recombinant CHGB (3.0 lM) full-length, or pre-digested by plasmin. The digestion reaction (1 h) contained CHGB (10 lM) and plasmin (2 lM) in a reaction volume of 120 lL of 10 mM Tris-Cl, pH 8.0 and NaCl 150 mM. After digestion, peptides were purified (and intact plasmin removed) by C18 cartridge (Waters, Milford, MA, USA), lyophilized, and suspended in water.
LC-MS/MS
In one experiment, plasmin-digested human CHGB (without added aprotinin) was subjected to LC-MS/MS, for identification of cleavage sites. Plasmin-digested peptides were analyzed by HPLC coupled to tandem mass spectroscopy (LC-MS/MS) using nanospray ionization, in a Triple TOF 5600 hybrid mass spectrometer (AB-SCIEX) interfaced with nano-scale reversedphase HPLC (Tempo) using a 10 cm-100 micron ID glass capillary packed with 5-lm C-18 ZorbaxTM beads (Agilent Technologies, Santa Clara, CA, USA). Peptides were eluted from the C18 column into the mass spectrometer using a linear gradient (5-60%) of acetonitrile (ACN) at a flow rate of 250 lL/min for 1 h. The buffers used to create the ACN gradient were: Buffer A (2% ACN, 0.2% formic acid, and 0.005% TFA 12 ,i nH 2 O) and Buffer B (0.2% formic acid, and 0.005% TFA in ACN). MS/MS data were acquired as follows: MS-1 data were obtained for 250 ms at m/z of 400-1250 Da, while MS-2 data spanned m/z of 50-2000 Da. The independent data acquisition parameters were as follows: MS-1 TOF 250 ms, followed by 50 MS-2 events of 25 ms each, and independent data acquisition criteria of over 200 counts (threshold) and charge state +2t o+4, with a 4 s exclusion. Finally, collected data were analyzed by MASCOT â (Matrix Sciences) and Protein Pilot 4.0 14 13 (AB-SCIEX) for peptide sequence identification, with reference to the human CHGB amino acid sequence as template (UniProt P05060, NCBI NP_001810).
CHGB peptide synthesis
Five peptides were synthesized by solid-phase F-moc chemistry, with molecular mass verified by electrospray mass spectrometry (Mimotopes, Minneapolis, MN, USA). CHGB regions were selected for a preponderance of sequence features bearing similarity to the catecholamine release-inhibitory CHGA fragment catestatin (human CHGA ) (Mahata et al. 1999; Mahapatra et al. 2005) : basic isoelectric point (pI), basic amino acids (Arg, Lys; including dibasic or tribasic sites), hydrophobicity or aromaticity (Leu, Ile, Val, Phe, Tyr, His); amphiphilicity (alternating hydrophobic and cationic residue side chains); and relative abundance of the product after cleavage out of the CHGB precursor in chromaffin granules in vivo Hook et al. 2010; Wegrzyn et al. 2010) . The synthetic sequences were as follows: hCHGB [60] [61] [62] [63] [64] [65] [66] [67] to Ca 2+ -free buffer (secretion buffer without 2 mM CaCl 2 ), and drugs were to the labeled buffer at 37°C. The cells were incubated with labeled buffer under different conditions for 5 min at room temperature 15
. Calcium uptake was stopped simultaneously in all six wells by inversion of the plate, so all wells were decanted together, followed by prompt addition of ice-cold release buffer containing 2 mL of 1 mmol/L LaCl 3 for termination of further uptake of extracellular labeled calcium. The culture dishes were then rinsed twice with ice-cold release buffer. One mL of cell lysis buffer was added to cells in each well and collected for liquid scintillation counting. The data were expressed as counts per minute per well.
Statistical analyses
Results are expressed as mean AE 1 SEM. The reported 'n' refers to the number of replications. Data were evaluated by Student's t-test or ANOVA, followed by post hoc tests, in Excel (Microsoft, Bellevue, WA, USA) or SPSS-17 (Chicago, IL, USA). p-values < 0.05 were considered statistically significant.
Results
Silencing CHGB expression in chromaffin cells by siRNA Introduction of rat CHGB siRNA into PC12 dose-dependently decreased CHGB protein expression on immunoblot. CHGB siRNA knocked down CHGB protein by 81% (p = 0.02) at 7.5 nM and > 95% at 15 nM (p = 0.01, Fig. 1a ). In the catecholamine storage/synthesis pathway, after CHGB siRNA treatment real-time qPCR indicated that CHGB mRNA declined by 46% (p < 0.05), while these mRNAs increased: Chga (by 35% p < 0.05); and Dbh (by 243%, p = 0.003). There were no changes in mRNAs encoding Scg2 or Th (Fig. 1b) . The increase in Dbh transcription suggests negative feedback control by cellular catecholamine content, but the mechanism of such an effect is not established.
Effect of CHGB siRNA knockdown on catecholamine storage, uptake, or secretion in chromaffin cells After CHGB siRNA, transmission electron micrographs indicated a~48% less of dense core granule abundance in CHGB siRNA treated PC12 cells compared with control cells (Fig. 1c) . There were 25.4 AE 2.7 granules per 100 lm 2 in control PC12 cells and 13.3 AE 2.5 granules per 100 lm 2 in CHGB siRNA PC12 cells (p = 0.006, Fig. 1d left) . Average granule diameter was 63.4 AE 2.75 nm after CHGB siRNA, versus 92.8 AE 1.87 nm in control cells, thus declining bỹ 32% during knockdown (p < 0.001, Fig 1d right) . Uptake of exogenous catecholamines in CHGB siRNA-silenced cells declined by~78% compared to control (p < 0.0001, Fig. 1e ). Secretion of catecholamines during nicotinic cholinergic stimulation also declined by~75% (p = 0.005, Fig. 1e ). Basal secretion of catecholamine was also diminished in CHGB siRNA-silenced cells (p = 0.023, Fig. 1e ).
CHGB targeted ablation in vivo: CHGB knockout mice
Morphology (transmission EM of the adrenal medulla) Transmission EM indicated that dense core granules in the adrenal medulla of CHGB(À/À) mice displayed both loss of abundance and decline in size. In CHGB knockout mice, the number of granules was 9.1 AE 0.55 per lm 2 in CHGB(+/+) mice versus 5.9 AE 0.59 per in CHGB(À/À) mice, thus declining by~35% (p < 0.001, Fig. 2a ). The average diameter of dense core granules was 173.1 AE 6.3 nm in CHGB(+/+) mice, declining by~44% to 97.4 AE 3.6 in CHGB(À/À) mice (p < 0.001, Fig. 2a ).
Catecholamine secretion in vivo
Here, we found that plasma concentrations of both norepinephrine and epinephrine were significantly higher in CHGB knockout mice, with norepinephrine increasing from 22.6 AE 3.4 to 36.9 AE 4.2 ng/mL in CHGB(À/À) mice, and epinephrine from 8.1 AE 0.9 to 14.7 AE 2.2 ng/mL: increments of~1.6-fold for norepinephrine and~1.7-fold for epinephrine (each p < 0.05, Fig. 2b ).
Over-expression of CHGB in chromaffin cells by lentivirus transduction After transduction by CHGB-lentivirus, over-expressing PC12 cells were selected by flow cytometry based on the tdTomato photoprotein red fluorescence ( Figure S2 ). Transduction caused an increase of CHGB protein by~127% compared to control cells (Fig. 3a) , while the abundance of dense core granules increased from 22.2 AE 4.4 per highpower field (2.0 9 10 À10 m 2 ) in control cells to 50.3 AE 8.3 in virus-infected cells (p = 0.01, Fig. 3b and c) . The diameter of granules was unchanged, at 92.8 AE 1.87 nm in control cells versus 90.9 AE 2.98 nm in CHGB over-expressing cells. Over-expression of CHGB caused increased exogenous catecholamine uptake by~14% (p = 0.019), 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 . (b) Expression of catecholamine pathway (storage, synthesis) genes in CHGB siRNA-silenced PC12 cells. The rat CHGB siRNA siGENOME 'smart pool' was transfected at 15 nM into PC12 cells and transcript expression was scored by real-time qPCR, and normalized to the signal for b-actin. Each condition was repeated four times. During knockdown, the CHGB transcript was underexpressed, while Chga and Dbh were over-expressed, but Scg2 and Th were unchanged. (c) Visualization of dense-core granules in CHGB siRNA-silenced PC12 cells by transmission electron microscopy (EM). PC12 cells were transfected with the rat CHGB siRNA siGENOME 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 but did not alter nicotinic cholinergic stimulation of catecholamine release (p < 0.05, Fig. 3d ).
Extra-cellular effects of CHGB and its proteolytic fragments: catecholamine release from chromaffin cells Both intact CHGB itself and its plasmin-digested fragments inhibited nicotinic cholinergic-stimulated catecholamine release, with~53% reduction by CHGB itself and~72% reduction by its fragments (p < 0.01, Fig. 4a, left) . In contrast, CHGB or its fragments only moderately inhibited membrane depolarization-stimulated catecholamine release: 23% reduction by CHGB and~32% by its proteolytic fragments (p < 0.01, Fig. 4a, right) .
Screening CHGB peptides for inhibition of nicotinic cholinergic secretion
The 5 synthetic CHGB peptides displayed a spectrum of inhibitory effects on nicotinic cholinergic secretion, with the shortest fragment CHGB[60-67] (KFEVRLLR) exerting the most prominent effect, reducing nicotinic stimulation's effect by~41%. As a positive control, human catestatin (CHGA ) completely abrogated nicotine's effect (Fig. 4b,  left) . In contrast, synthetic CHGB peptides had little or no effect on catecholamine release when stimulated by membrane depolarization (Fig. 4b, middle) , suggesting an element of nicotinic pathway specificity for the secretory effect. (Fig. 4b, right) (Kennedy et al. 1998) , and more specifically within an amphiphilic helical (or coiledcoil) patch, as previously described for both CHGA and CHGB (Mosley et al. 2007 ). Endoproteolytic cleavage of CHGB in the region of the active secretory peptide We analyzed plasmin-liberated human CHGB peptides by LC-MS/MS, to position the cleavage sites for this chromaffin cell endoproteolytic system. In the region of the active peptide (Table 1a) , extensive cleavage was noted, primarily at monobasic sites (i.e., R or K), though also at dibasic site R 46 K 47 . As a control to explore endoprotease cleavage targets elsewhere in CHGB, we also evaluated a region (CHGB 565-596 ) containing three dibasic sites -K 566 R 567 , K 578 R 579 , and R 595 K 596 K 597 -that bound two putative peptides for liberation and CHGB [580] [581] [582] [583] [584] [585] [586] [587] [588] [589] [590] [591] [592] [593] [594] ); each of these three dibasic sites was utilized by plasmin, and the expected peptides were formed (Table 1b) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 Discussion Overview The chromogranin/secretogranin acidic proteins are mainly located within neuroendocrine secretory vesicles such as chromaffin granules and large dense-core vesicles of monoaminergic neurons (Huttner et al. 1991; Taupenot et al. 2003) . In these organelles, chromogranins constitute the main protein component of the intravesicular matrix. An important property of chromogranins is their ability to bind solutes, thereby allowing large dense-core vesicles to accumulate large amounts of catecholamines while maintaining their osmotic stability (Helle et al. 1985; Videen et al. 1992) , an effect essential for the maintenance of neurosecretory activity. Several functions have been proposed for chromogranin B (CHGB), including granule biogenesis and sorting (Natori and Huttner 1996; Huh et al. 2003) , Ca 2+ sequestration and release (Yoo and Jeon 2000) , and a source of bioactive peptides (Strub et al. 1995; Winkler et al. 1998) . Alterations in CHGB expression accompany several human diseases of disordered neurotransmitter storage or release, such as hypertension (Zhang et al. 2009 (Zhang et al. , 2010 (Zhang et al. , 2011 , schizophrenia (Landen et al. 1999; Marksteiner et al. 2000) , and Alzheimer disease (Marksteiner et al. 2002) . While previous studies of CHGB abundance suggested alterations in storage granule abundance, quantitative studies of physiological processes underpinning catecholamine synthesis, uptake, storage, and secretagogue-triggered release have been lacking.
CHGB under-and over-expression in catecholaminergic cells, as well as in vivo
In PC12 cells, si-RNA silencing successfully diminished CHGB protein expression, with consequent reduction of chromaffin granule abundance, uptake of exogenous (a) CHGB amino-terminal region harboring the active secretory peptide Peptide_1 
Alignments by Clustal Omega (1.2.0) 18 . Legend: Italics = Paired basic residues; Underlined = Active peptide tested; No. Obs. = Number of times that peptide was observed in spectra . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 catecholamines, and secretagogue-stimulated catecholamine release (Fig. 1e) . Conversely, expression viral transduction successfully increased CHGB expression, with an increase in chromaffin granule abundance, but only minor changes in cellular ability to uptake catecholamines or respond to secretory stimulation (Fig. 3d) . Thus, the range of CHGB concentrations between physiological and zero have profound consequences for catecholamine metabolism, while elevation of CHGB beyond the physiological range does influence granule morphogenesis, but seems to have fewer physiological effects, suggesting a sufficient or saturating CHGB concentration under basal circumstances.
Both we (Fig. 1b) and Diaz-Vera et al. (2010) found changes in expression of other chromaffin cell mRNAs during diminution of CHGB expression, especially overexpression of Chga mRNA. We speculate that such an increase may have dampened the already impressive consequences of CHGB depletion (Fig. 1e) . Diaz-Vera et al. (2010) noted diminished adrenal medullary storage of epinephrine and norepinephrine, consistent with our finding of decreased catecholamine uptake capacity (Fig. 1e) .
In vivo (targeted ablation of the mouse CHGB locus), we found similar changes in granule morphology (Fig. 2a) , with apparently unregulated catecholamine release (Fig. 2b) , which may underlie the substantially elevated blood pressure observed in the CHGB(À/À) mouse (Zhang et al. 2009 ). Of note, we previously observed similar catecholamine release and blood pressure effects in the Chga knockout mouse (Mahapatra et al. 2005) .
Using an expressed frog CHGA (fCHGA) cDNA and a nonchromaffin cell line (COS-7), Montero-Hadjadje, et al. demonstrated that CHGA has the intrinsic capacity to induce formation of mobile secretory granules and to promote the sorting and release of peptide hormones (Montero-Hadjadje et al. 2009). Our finding of a role for CHGB on the biogenesis of dense core granules (in chromaffin and PC12 cells) indicates that these two homologous proteins exert similar functions.
CHGB peptide regions on catecholamine release
The CHGA peptide catestatin (human CHGA ) inhibits the physiological (nicotinic cholinergic) pathway of catecholamine release in chromaffin cells (Mahata et al. 1999; Mahapatra et al. 2005) and polymorphisms in the human catestatin region are associated with risk of hypertension (Rao et al. 2007 ). Here, we observed a similar (though less potent) inhibitory effect on nicotinic-stimulated secretion for CHGB and its proteolytic fragments (Fig. 4a) . We then synthesized several peptides that potentially mimic the effects of catestatin, and found that such peptides can inhibit nicotinic cholinergic-stimulated catecholamine release (Fig. 4b left) and cationic signal transduction (Fig. 4c ) in chromaffin cells, albeit at lower potency and efficacy than catestatin. The complete lack of effect of CHGB synthetic peptides on catecholamine secretion triggered by membrane depolarization (Fig. 4b center) reinforces the specificity of such peptides for the nicotinic cholinergic pathway.
The active human CHGB region is completely conserved across mammalian species (human, rat, mouse), and the target region is extensively cleaved by the chromaffin cell plasmin endoproteolytic system (Table 1a) , though we have not yet positioned the precise boundaries of the active peptide as formed in vivo; as a control, the same system exerts the expected cleavage pattern on multiple dibasic sites in the human CHGB substrate (Table 1b) . A more extensive synthetic peptide scan across the entire CHGB protein (or its Reciprocal actions of chromogranin B (CHGB) on catecholamine storage (stimulation) and release (inhibition). The figure synthesizes the consequences of our CHGB results for these physiological processes. Within chromaffin cells, CHGB participates in assembly of catecholamine secretory vesicles (dense-core granules), and governs the secretory capacity of these granules under the nicotinic stimulation. After proteolytic cleavage and release into the extracellular space, CHGB (and particularly its peptide hCHGB [60] [61] [62] [63] [64] [65] [66] [67] ) seems to exert a negative feedback effect to inhibit the secretory response to acetylcholine . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 highly conserved regions) could better establish the active region(s) of the protein.
Conclusions and perspectives
Within chromaffin cells, CHGB participates in assembly of catecholamine secretory vesicles (dense-core granules), and governs the secretory capacity of these granules under the nicotinic stimulation. After proteolytic cleavage and release into the extracellular space, CHGB (and particularly its peptide hCHGB [60] [61] [62] [63] [64] [65] [66] [67] ) seems to exert a negative feedback effect to inhibit the physiological secretory response to acetylcholine. The autocrine effects of released/processed CHGB on secretion (Fig. 5) would be most likely to occur on chromaffin cells, whose chromaffin granules (or large dense core vesicles) typically contain both chromogranins and catecholamines, though even sympathetic nerve termini which contain substantial numbers of small dense core vesicles, without chromogranins also harbor some chromogranin-bearing large dense core vesicles (O 'Connor et al. 1991) .
Derangements of CHGB expression may thus lead to impaired catecholamine storage, with consequently elevated constitutive catecholamine release, eventuating in systemic hypertension. Our data provide direct bi-directional evidence implicating CHGB in vesicular storage of catecholamines, and also novel evidence implicating released CHGB in control of exocytosis. Thus, CHGB emerges as a multifunctional protein/peptide, with both intra-cellular and extracellular activities (Fig. 5) , whose novel properties may contribute to a spectrum of catecholaminergic disease states.
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